Ad is loading...
MENU

ARCT Stock Arcturus Therapeutics Holdings (ARCT, $16.27) RSI Indicator left the oversold zone on November 18, 2024

A.I.dvisor
at Tickeron.com
Loading...
ARCT - Arcturus Therapeutics Holdings
RSI signal
Bullish Trend
Odds of UP Trend
Tickeron
RSI signal
Price: $16.27
Daily change: +$0.25 (+1.56%)
Daily volume: 939.5K
Industry: Biotechnology
This is a signal that ARCT's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options. A.I.dvisor looked back and found 29 similar cases where ARCT's RSI Indicator left the oversold zone, and in of them led to a successful outcome. Odds of Success:

ARCT's RSI Oscillator ascends from oversold territory

The RSI Indicator for ARCT moved out of oversold territory on November 18, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In of the 29 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .

ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 15, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ARCT as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ARCT turned negative on November 15, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

ARCT moved below its 50-day moving average on October 21, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on October 22, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ARCT entered a downward trend on November 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.749) is normal, around the industry mean (13.913). P/E Ratio (0.000) is within average values for comparable stocks, (89.373). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.810). ARCT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (3.197) is also within normal values, averaging (222.803).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ARCT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ARCT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of technology and therapeutics for rare diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
10628 Science Center Drive
Phone
+1 858 900-2660
Employees
180
Web
https://www.arcturusrx.com